Heart rate variability and quality of life in dogs with mitral valve disease treated with metoprolol

Detalhes bibliográficos
Autor(a) principal: Beluque, Tamyris
Data de Publicação: 2021
Outros Autores: Camacho, Aparecido Antonio, Ampuero, Roberto Navarrete, Braz, Jaislane Bastos, Kirnew, Murillo Daparé, Canola, Raphaela Arantes Marques, Carvalho, Elizabeth, Sousa, Marlos Gonçalves
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Brazilian Journal of Veterinary Medicine
Texto Completo: https://rbmv.org/BJVM/article/view/1192
Resumo: Mitral valve disease (MVD) is a progressive disease that can reduce cardiac output. Activation of the sympathetic autonomic nervous system is one of the body’s first responses in order to maintain cardiac output, but may have deleterious effects on the cardiovascular system. This study investigated the effect of metoprolol on heart rate variability and quality of life in dogs with severe MVD (stage C, according to the guidelines of the American College of Veterinary Internal Medicine). Eight dogs between nine and thirteen years of age were enrolled and screening tests such as complete blood count, serum biochemistry profile, systolic blood pressure, thoracic radiographs, electrocardiogram, echocardiogram and long-term electrocardiography (24 hours) were performed. The patients were treated with enalapril, furosemide, spironolactone, and pimobendan until considered clinically stable, and metoprolol was then added to the therapy. One month later, all animals were re-assessed. Owners responded to a questionnaire about their dog’s quality of life before and after beta-blocker therapy. The value for pNN50 (percentage difference between adjacent N-N intervals more than 50 ms) was significantly higher (P=0.039) after treatment with metoprolol, indicating higher heart rate variability as indicated by the increased parasympathetic component. Furthermore, quality of life was improved in 30% of patients after metoprolol was initiated. The results suggest that treatment with beta-blockers in dogs with stage C MVD may yield additional benefits in comparison to standard CHF treatment.
id SBMV-1_593c704ebcd89264dfd84083bbbd40fa
oai_identifier_str oai:ojs.rbmv.org:article/1192
network_acronym_str SBMV-1
network_name_str Brazilian Journal of Veterinary Medicine
repository_id_str
spelling Heart rate variability and quality of life in dogs with mitral valve disease treated with metoprolol Variabilidade da frequência cardíaca e qualidade de vida em cães com doença valvar mitral tratados com metoprolol sistema nervoso autônomo, betabloqueadores, holter, pNN50autonomic nervous system, beta-blockers, holter, pNN50.Mitral valve disease (MVD) is a progressive disease that can reduce cardiac output. Activation of the sympathetic autonomic nervous system is one of the body’s first responses in order to maintain cardiac output, but may have deleterious effects on the cardiovascular system. This study investigated the effect of metoprolol on heart rate variability and quality of life in dogs with severe MVD (stage C, according to the guidelines of the American College of Veterinary Internal Medicine). Eight dogs between nine and thirteen years of age were enrolled and screening tests such as complete blood count, serum biochemistry profile, systolic blood pressure, thoracic radiographs, electrocardiogram, echocardiogram and long-term electrocardiography (24 hours) were performed. The patients were treated with enalapril, furosemide, spironolactone, and pimobendan until considered clinically stable, and metoprolol was then added to the therapy. One month later, all animals were re-assessed. Owners responded to a questionnaire about their dog’s quality of life before and after beta-blocker therapy. The value for pNN50 (percentage difference between adjacent N-N intervals more than 50 ms) was significantly higher (P=0.039) after treatment with metoprolol, indicating higher heart rate variability as indicated by the increased parasympathetic component. Furthermore, quality of life was improved in 30% of patients after metoprolol was initiated. The results suggest that treatment with beta-blockers in dogs with stage C MVD may yield additional benefits in comparison to standard CHF treatment.A doença valvar mitral (DVM) é progressiva e pode levar à redução do débito cardíaco. A ativação do sistema nervoso autônomo simpático é uma das primeiras tentativas para manter o débito cardíaco, no entanto pode culminar em efeitos deletérios para o sistema cardiovascular quando ativada de forma crônica. Este estudo investigou o efeito do metoprolol na variabilidade da frequência cardíaca e qualidade de vida de cães com DVM em estágio C, seguindo a classificação do American College of Veterinary Internal Medicine. Foram avaliados oito cães entre nove e treze anos com DVM de classe C. Foram realizados exames de triagem, tais como hemograma, perfil bioquímico sérico, aferição da pressão arterial sistólica, radiografias torácicas, eletrocardiograma, ecocardiograma e eletrocardiograma de longa duração (24 horas). Os pacientes foram tratados com enalapril, espironolactona, furosemida e pimobendan até a estabilização do quadro e, após, receberam metoprolol durante um mês para então serem submetidos aos mesmos exames. Os tutores responderam um questionário sobre a qualidade de vida de seus cães antes e após a terapia com o betabloqueador. O pNN50 (porcentagem dos intervalos RR adjacentes com diferença de duração maior que 50ms) apresentou aumento significativo (P=0.039) após o tratamento com metoprolol, indicando maior variabilidade da frequência cardíaca por permitir a prevalência do sistema nervoso autônomo parassimpático. Além disso, 30% dos pacientes apresentaram melhora na qualidade de vida após instituição do metoprolol. Considerando os resultados obtidos é possível inferir que o tratamento com o betabloqueador em cães com doença valvar mitral pode ser considerado uma ferramenta terapêutica adicional na terapia da insuficiência cardíaca congestiva classe C.Sociedade de Medicina Veterinária do Estado do Rio de Janeiro.2021-06-21info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionpeer reviewedAvaliado pelos paresapplication/pdftext/xmlhttps://rbmv.org/BJVM/article/view/119210.29374/2527-2179.bjvm003020Brazilian Journal of Veterinary Medicine; Vol. 43 No. 1 (2021); e003020Revista Brasileira de Medicina Veterinária; v. 43 n. 1 (2021); e0030202527-21790100-2430reponame:Brazilian Journal of Veterinary Medicineinstname:Sociedade de Medicina Veterinária do Estado do Rio de Janeiro (SOMVERJ)instacron:SBMVenghttps://rbmv.org/BJVM/article/view/1192/1092https://rbmv.org/BJVM/article/view/1192/1217Copyright (c) 2021 Tamyris Beluque, Aparecido Antonio Camacho, Roberto Navarrete Ampuero, Jaislane Bastos Braz, Murillo Daparé Kirnew, Raphaela Arantes Marques Canola, Elizabeth Carvalho, Marlos Gonçalves Sousahttp://creativecommons.org/licenses/by/4.0info:eu-repo/semantics/openAccessBeluque, TamyrisCamacho, Aparecido AntonioAmpuero, Roberto NavarreteBraz, Jaislane BastosKirnew, Murillo DaparéCanola, Raphaela Arantes MarquesCarvalho, ElizabethSousa, Marlos Gonçalves2022-06-27T12:19:10Zoai:ojs.rbmv.org:article/1192Revistahttps://rbmv.org/BJVMONGhttps://rbmv.org/BJVM/oaicontato.rbmv@gmail.com2527-21790100-2430opendoar:2022-06-27T12:19:10Brazilian Journal of Veterinary Medicine - Sociedade de Medicina Veterinária do Estado do Rio de Janeiro (SOMVERJ)false
dc.title.none.fl_str_mv Heart rate variability and quality of life in dogs with mitral valve disease treated with metoprolol
Variabilidade da frequência cardíaca e qualidade de vida em cães com doença valvar mitral tratados com metoprolol
title Heart rate variability and quality of life in dogs with mitral valve disease treated with metoprolol
spellingShingle Heart rate variability and quality of life in dogs with mitral valve disease treated with metoprolol
Beluque, Tamyris
sistema nervoso autônomo, betabloqueadores, holter, pNN50
autonomic nervous system, beta-blockers, holter, pNN50.
title_short Heart rate variability and quality of life in dogs with mitral valve disease treated with metoprolol
title_full Heart rate variability and quality of life in dogs with mitral valve disease treated with metoprolol
title_fullStr Heart rate variability and quality of life in dogs with mitral valve disease treated with metoprolol
title_full_unstemmed Heart rate variability and quality of life in dogs with mitral valve disease treated with metoprolol
title_sort Heart rate variability and quality of life in dogs with mitral valve disease treated with metoprolol
author Beluque, Tamyris
author_facet Beluque, Tamyris
Camacho, Aparecido Antonio
Ampuero, Roberto Navarrete
Braz, Jaislane Bastos
Kirnew, Murillo Daparé
Canola, Raphaela Arantes Marques
Carvalho, Elizabeth
Sousa, Marlos Gonçalves
author_role author
author2 Camacho, Aparecido Antonio
Ampuero, Roberto Navarrete
Braz, Jaislane Bastos
Kirnew, Murillo Daparé
Canola, Raphaela Arantes Marques
Carvalho, Elizabeth
Sousa, Marlos Gonçalves
author2_role author
author
author
author
author
author
author
dc.contributor.author.fl_str_mv Beluque, Tamyris
Camacho, Aparecido Antonio
Ampuero, Roberto Navarrete
Braz, Jaislane Bastos
Kirnew, Murillo Daparé
Canola, Raphaela Arantes Marques
Carvalho, Elizabeth
Sousa, Marlos Gonçalves
dc.subject.por.fl_str_mv sistema nervoso autônomo, betabloqueadores, holter, pNN50
autonomic nervous system, beta-blockers, holter, pNN50.
topic sistema nervoso autônomo, betabloqueadores, holter, pNN50
autonomic nervous system, beta-blockers, holter, pNN50.
description Mitral valve disease (MVD) is a progressive disease that can reduce cardiac output. Activation of the sympathetic autonomic nervous system is one of the body’s first responses in order to maintain cardiac output, but may have deleterious effects on the cardiovascular system. This study investigated the effect of metoprolol on heart rate variability and quality of life in dogs with severe MVD (stage C, according to the guidelines of the American College of Veterinary Internal Medicine). Eight dogs between nine and thirteen years of age were enrolled and screening tests such as complete blood count, serum biochemistry profile, systolic blood pressure, thoracic radiographs, electrocardiogram, echocardiogram and long-term electrocardiography (24 hours) were performed. The patients were treated with enalapril, furosemide, spironolactone, and pimobendan until considered clinically stable, and metoprolol was then added to the therapy. One month later, all animals were re-assessed. Owners responded to a questionnaire about their dog’s quality of life before and after beta-blocker therapy. The value for pNN50 (percentage difference between adjacent N-N intervals more than 50 ms) was significantly higher (P=0.039) after treatment with metoprolol, indicating higher heart rate variability as indicated by the increased parasympathetic component. Furthermore, quality of life was improved in 30% of patients after metoprolol was initiated. The results suggest that treatment with beta-blockers in dogs with stage C MVD may yield additional benefits in comparison to standard CHF treatment.
publishDate 2021
dc.date.none.fl_str_mv 2021-06-21
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
peer reviewed
Avaliado pelos pares
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv https://rbmv.org/BJVM/article/view/1192
10.29374/2527-2179.bjvm003020
url https://rbmv.org/BJVM/article/view/1192
identifier_str_mv 10.29374/2527-2179.bjvm003020
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv https://rbmv.org/BJVM/article/view/1192/1092
https://rbmv.org/BJVM/article/view/1192/1217
dc.rights.driver.fl_str_mv http://creativecommons.org/licenses/by/4.0
info:eu-repo/semantics/openAccess
rights_invalid_str_mv http://creativecommons.org/licenses/by/4.0
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
text/xml
dc.publisher.none.fl_str_mv Sociedade de Medicina Veterinária do Estado do Rio de Janeiro.
publisher.none.fl_str_mv Sociedade de Medicina Veterinária do Estado do Rio de Janeiro.
dc.source.none.fl_str_mv Brazilian Journal of Veterinary Medicine; Vol. 43 No. 1 (2021); e003020
Revista Brasileira de Medicina Veterinária; v. 43 n. 1 (2021); e003020
2527-2179
0100-2430
reponame:Brazilian Journal of Veterinary Medicine
instname:Sociedade de Medicina Veterinária do Estado do Rio de Janeiro (SOMVERJ)
instacron:SBMV
instname_str Sociedade de Medicina Veterinária do Estado do Rio de Janeiro (SOMVERJ)
instacron_str SBMV
institution SBMV
reponame_str Brazilian Journal of Veterinary Medicine
collection Brazilian Journal of Veterinary Medicine
repository.name.fl_str_mv Brazilian Journal of Veterinary Medicine - Sociedade de Medicina Veterinária do Estado do Rio de Janeiro (SOMVERJ)
repository.mail.fl_str_mv contato.rbmv@gmail.com
_version_ 1798313111526047744